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Hair Today, Gone Tomorrow: Minireview
Transgenic Mice with Human
Repair Deficient Hair Disease
chromosome 19q13.2, contains 23 exons, and ex-
presses a 2.4 kb transcript. XPD is a 760 amino acid
protein that contains 7 distinctive helicase motifs and
functions in vitro as a 59-to-39 helicase that unwinds
DNA in the vicinity of damaged sites. Early studies indi-
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cated XP-D cells had a severe defect in the excision of
the major UV light-induced photoproducts from DNA,
the [5-5,6-6] cyclobutane pyrimidine dimer, and the [6-DNA repair was once an arcane special interest of a
4] photoproduct, and were extremely sensitive to killingsmall circle of radiobiologists who realized that the overt
from UV light (Bootsma et al., 1998). However, therebiological manifestations of radiation action must in-
were also puzzling complexities: there are reports thatvolve extensive cellular metabolism acting on the initial
some XP-D cells have other defects, including reducedintracellular deposits of miniscule amounts of energy.
levels of apurinic endonucleases class I and III, whichRepair has now emerged as a major player in the strat-
are inseparable activities associated with ribosomal pro-egy for cell survival, and repair genes represent a signifi-
tein S3 (Kim et al., 1995), and catalase (Vuillaume et al.,cant component of every sequenced genome. With this
1992; Quillet et al., 1997), an enzyme involved in theemergence has come a multitude of surprises: solving
response of cells to oxidative damage. XP-D cells alsothe mechanisms of DNA repair has revealed important
showed reduced expression of intracellular adhesionlinks to major pathways of normal cell metabolism. No-
molecule (ICAM-1) after UV irradiation (Ahrens et al.,where has the surprise been greater than the unex-
1997), indicating abnormalities in a cell surface receptorpected linkage between nucleotideexcision repair (NER)
molecule involved in the immune response. The catalaseand the regulation of RNA polymerase II±dependent
deficiency is restored to normal after transfection of atranscription (Schaeffer et al., 1993). Gene products
cDNA expressing XPD, (Quillet et al., 1997) proving it toknown to be critical to NER, from their identification with
be a direct consequence of mutations in XPD. Clearly,complementation groups of the human NER-deficient
XP-D cells have a wider defect in cellular regulationdisease xeroderma pigmentosum (XP), were found to be
involving either altered transcription of downstreamamong the nine components of the basal transcription
genes or secondarymodifications through phosphoryla-factor TFIIH (Bootsma et al., 1998). Mutations in many
tion or other alterations. Further complexities came withof these TFIIH components have been found to confer
the discovery of other diseases, especially TTD andan ultraviolet (UV)±sensitive phenotype on S. cerevisiae,
Cockayne syndrome (CS) in which patients are UV sensi-but not all have been so characterized in mammalian
tive and, to the surprise of many, have mutations withincells (Friedberg et al., 1995, 1997; Wang et al., 1995).
the XPD gene in some cases (Taylor et al., 1997).One of these genes, human XPD, the homolog of S.
TTD is a heterogeneous disease in which patientscerevisiae RAD3, has proved to be the most interesting
have abnormalities in the hair, skin (ichthyosis), teethand enigmatic of these genes, as well as the richest in
and nails, and nervous system (microcephaly, impairedcomplexity.
intelligence, dysmyelination), as well as developmentalThe new report by Jan de Boer and colleagues in the
problems (Bootsma et al., 1998). The characteristic brit-current issue of Molecular Cell (de Boer et al., 1998a)
tle hair, which shows a banding pattern in polarizedintroduces a novel approach to developing true transgenic
light, is due to deficiencies in sulfur-containing (cysteine)models of a human XPD disease, and provides confirma-
matrix proteins. Some but not all TTD patients showtion of the relationship between a specific mutation and
increased sun sensitivity. The NER system in TTD cellsthe clinical features of one of the diseases associated
appears very variable, but according to some reportswith XPD, the photosensitive hair-loss disease trichothi-
can still excise [6-4] photoproducts from the DNA, and toodystrophy (TTD) (Bootsma et al., 1998).
a lesser extent cyclobutane dimers (Eveno et al., 1995),The first indications that XPD mutations were likely
although there is great variability among different pa-to have complex phenotypes came with the observation
tients. CS patients also show increased sun sensitivity,that loss-of-function mutations in RAD3 were lethal
with developmental disorders showing reduced stature,(Friedberg et al., 1995). A subsequent study showed
microcephaly with cerebellar calcification, dysmyelina-that knockout of the XPD gene in mouse resulted in
tion, and retinal abnormalities (Bootsma et al., 1998).homozogyote embryos that failed to proceed beyond
Both TTD and CS involve several genes that are specificthe preimplantation stage (de Boer et al., 1998b). How
to the disorders (TTDA, CSA, CSB), but some patientsthen could mutations in this essential gene give rise to
with associated XP-like symptoms surprisingly haveviable human beings, albeit with severe disease? Clearly,
XPD mutations. Several different diseases can thereforethe precise mutations within the gene were critical for
be caused by mutations in the XPD gene.the nature of the disease.
The distribution of mutations in the XPD gene did notXP-D was originally a complementation group classifi-
at first correspond with specific clinical disorders andcation for a severe form of XP with both skin cancer
was further complicated by neutral and conservativeand neurological degeneration; the gene for this group
polymorphisms. An important step came with the real-was cloned as the gene (ERCC2) that complemented
the homologous Chinese hamster UV-sensitive comple- ization that since inactivating mutations in RAD3 were
lethal (Friedberg et al., 1995), then any mutations in XPDmentation group 2 (Weber et al., 1990). The gene is on
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Figure 1. Design of Targeting Vector to Intro-
duce a Human Mutation into Exon 22 of the
Mouse XPD Gene
See text for details.
that resulted in a nonfunctional protein which destroyed 59 direction to a HindIII site between exons 12 and 13.
TFIIH function, e.g., splice sites and frame shifts, might The dominant selectable marker for neomycin resis-
be irrelevant to theclinical disease. Only missense muta- tance and neutral sequences from b-globin including a
tions resulting in a changeof function would be relevant. poly(A) addition site, and the tk gene for counter selec-
Mutations corresponding to the human XPD mutations tion, were then added following the stop codon of the
were then tested for their capacity to complement a human fragment. This approach, called a ªgene±cDNA
lethal deletion in the correspondingS. pombe gene (Tay- fusion targeting,º allows for introduction of a specific
lor et al., 1997). Those that failed to complement could mutation with minimal alteration of the regulation of the
be excluded from consideration, and together with sub- gene, which remains under normal endogenous control
sequent sequence data, a pattern is evident. Mutations elements. The dominant and counter selection genes
in XPD that were associated with XPD patients showed were placed beyond the poly(A) addition site and tran-
a bias in favor of location in the helicase motifs of the scribed in the reverse direction to XPD, to avoid compli-
gene. Mutations associated with other clinical disorders cations that might result if they were part of the XPD
were more often outside the helicase motifs. This led to transcript itself. The only minor caveat in this particular
the definition of a ªrepair/transcription factor disease,º instance is that there is an additional expressed gene
in which mutations that affect a component of the tran- (KCL2) on the noncoding strand that overlaps the site
scription apparatus can have widespread and at pres- of the mutation in the XPD gene. But this appears to be
ent unpredictable effects on many downstream genes of no importance to the TTD phenotype of the animal,
(Bootsma et al., 1998). The helicase motif mutations in because no differences were seen after crossing the
the XPD gene are presumed to interfere with the pro- TTD mouse with an animal carrying a traditional knock-
tein's ability to function within the multiprotein complex out in the XPD gene 59 to the region of overlap. Any
that constitutes the repair machinery, and to unwind the gene with disease-related mutations at the 39 terminus
DNA, thus compromising both repair and transcription. of the gene can, in principle, be modeled in this way,
Mutations outside the helicase motifs arealso presumed and the gene±cDNA fusion targeting approach is likely
to compromise both functions but more especially the to find numerous applications.
transcription function of TFIIH, either by direct interfer-
The homozygote animals produced by this technique
ence in transcription or destabilization of the transcrip-
closely mimic the human TTD patients. The UV sensitiv-
tion complex. Destabilization of TFIIH might then be
ity, reduced cysteine-rich matrix proteins of the hair,
important in terminally differentiating tissues such as
growth delay, reduced fertility, and life span all faithfullyskin, hair, and the nervous system, as seen in TTD,
reproduce the human condition. In many human andwhere there may be cessation of de novo synthesis and
rodent cells, reductions in repair capacity tend first toa more rapid decline of an impaired transcription factor
affect a cell's capacity to repair cyclobutane dimers inactivity. It is surprising, however, that many of the sec-
nontranscribed regions of the genome, and it will beondary cellular features involving catalase, apurinic en-
especially interesting to learn whether the excisiondonuclease, and I-CAM show more abnormalities for
specificity of these TTD mouse cells for the major UV-XPD gene mutations than for TTD, which is not quite
induced photoproducts reflect that in human TTD cells.what would be expected if these changes were primarily
The animals showsymptoms of premature aging, includ-the result of changes in the transcription function.
ing osteoporosis, sclerosis of the skull, spinal kyphosis,The novelty of the new report (de Boer et al., 1998a)
and hair depigmentation. This is particularly interesting,is that the authors have created a transgenic animal that
because for many years there have been attempts todirectly copies a human mutation in XPD found in TTD,
relate repair capacity to aging with little definitive suc-by an innovative single-step procedure that is sure to
cess: for example, the more severe XP patients that onlybecome widely used (Figure 1). They chose an arginine-
lack excision repair capacity do not age prematurelyto-tryptophan (R722W; C2116T in exon 22) mutation
other than the photoaging of the skin (Cleaver, 1984;close to the 39 terminus of the XPD gene that is found
Bootsma et al., 1998), and the human premature agingin a TTD patient. A terminal 194 nt of the human XPD
diseases of progeria and Hutchinson-Gilford syndromecDNA containing this mutation was ligated in-frame to
exon 22 of mouse genomic DNA that extended in the appear to have normal radiation sensitivity and repair
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(Weichselbaum et al., 1980). The TTD mouse may indi- mouse made by traditional means also showed en-
hanced cancer induction from UVB and chemical carcin-cate that aging is more closely related to overall tran-
ogens (van der Horst et al., 1997). The observation withscription capacity and only secondarily to repair of en-
CSB could have been discounted by inferring that adogenously generated DNA damage.
knockout did not reflect accurately what occurs withThese animals therefore provide confirmation that the
point mutations in a human patient, even though somepoint mutation in XPD is causative for a TTD disease,
of these were functionally null. This explanation cannotand additional mutations in other unspecified genes do
be used for the present example of a TTD mouse thatnot have to be invoked, which had been a possibility.
models both the mutation and the major symptoms ofSubsequent construction of other point mutationswithin
the corresponding patient in other respects.a helicase motif to produce an XP-D mouse would fur-
Differences could be trivial, associated with differ-ther confirm this. The technique also opens up thepossi-
ences in life spans and accumulated sun exposure. Butbilities of reexamining other genes that have proven
there may be a more significant basis associated withto be embryonic lethals as knockouts and of making
the mouse genome itself. DNA repair studies, from theirspecific missense mutations to identify viable pheno-
inception, contained a nagging, unexplained observa-types that have not hitherto been related to NER. The
tion that the mouse, and mouse cells in culture particu-possibility of examining ERCC1 in the context of NER
larly, have an inherently reduced ability to repair thecomes to mind; the gene codes for part of the 59 excision
nontranscribed regions of the genome (Bohr, 1995). Thisnuclease of NER, no human patients are known to have
does not appear to be due to a difference in any of themutations in ERCC1, and homozygous null mice were
main components of the NER system, but may lie inrunted at birth and died shortly after (McWhir et al.,
some of the additional regulation of repair that occurs1993).
in vivo, such as the role of p53 interactions with TFIIH.The TTD animals recreate many physical features of
The differences between mouse models and human pa-TTD patients including thehair patterns, stunted growth,
tients in their response to carcinogens could thereforeand cachexia (wasted appearance), but only to a limited
depend on secondary species-specific factors that reg-extent their neurological degeneration (de Boer et al.,
ulate repair in different parts of their genomes.1998a). The mice only displayed occasional tremors, but
had normal myelination and general behavior. This is
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